$3.90
8.03% yesterday
Nasdaq, Jun 12, 10:00 pm CET
ISIN
US60853G1067
Symbol
MOLN
Sector
Industry

Molecular Partners AG - ADR Stock price

$3.90
-0.38 8.77% 1M
-1.65 29.73% 6M
-0.85 17.86% YTD
-1.90 32.76% 1Y
-17.10 81.43% 5Y
-17.10 81.43% 10Y
-17.10 81.43% 20Y
Nasdaq, Closing price Thu, Jun 12 2025
+0.29 8.03%
ISIN
US60853G1067
Symbol
MOLN
Sector
Industry

Key metrics

Market capitalization $142.70m
Enterprise Value $-38.65m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.52
EV/Sales (TTM) EV/Sales -6.30
P/S ratio (TTM) P/S ratio 23.28
P/B ratio (TTM) P/B ratio 0.82
Revenue growth (TTM) Revenue growth -60.65%
Revenue (TTM) Revenue $6.13m
EBIT (operating result TTM) EBIT $-75.52m
Free Cash Flow (TTM) Free Cash Flow $-73.99m
Cash position $184.36m
EPS (TTM) EPS $-1.80
P/E forward negative
P/S forward 235.80
EV/Sales forward negative
Short interest 0.29%
Show more

Is Molecular Partners AG - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Molecular Partners AG - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Molecular Partners AG - ADR forecast:

5x Buy
71%
2x Hold
29%

Analyst Opinions

7 Analysts have issued a Molecular Partners AG - ADR forecast:

Buy
71%
Hold
29%

Financial data from Molecular Partners AG - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
6.13 6.13
61% 61%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 22 22
40% 40%
354%
- Research and Development Expense 60 60
34% 34%
978%
-73 -73
33% 33%
-1,184%
- Depreciation and Amortization 2.92 2.92
2% 2%
48%
EBIT (Operating Income) EBIT -76 -76
32% 32%
-1,232%
Net Profit -67 -67
39% 39%
-1,088%

In millions USD.

Don't miss a Thing! We will send you all news about Molecular Partners AG - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Molecular Partners AG - ADR Stock News

Negative
Reuters
3 days ago
Swiss biotech firm Molecular Partners said on Tuesday that it plans to reduce its workforce by up to 40 positions, or around 24%, as part of a strategic review to boost operational efficiency and focus on key clinical assets.
Neutral
GlobeNewsWire
3 days ago
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announces that it has performed a strategic review of its c...
Neutral
GlobeNewsWire
25 days ago
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that members of the management team will participate in two upcoming investor conferences.
More Molecular Partners AG - ADR News

Company Profile

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.

Head office Switzerland
CEO Patrick Amstutz
Employees 159
Founded 2004
Website www.molecularpartners.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today